Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1C | Q14123 | 10/20 | 0.44 |
| ▸ | PDE1A | P54750 | 9/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 9/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13101678 | 0.94 | ALDH1A1 (0.43) | PDE1CPDE1APDE1BSMN1; SMN2ALDH1A1 | |
| SCHEMBL13102070 | 0.93 | SMN1; SMN2 (0.42) | PDE1CPDE1APDE1BSMN1; SMN2SIGMAR1 | |
| SCHEMBL3063535 | 0.92 | SMN1; SMN2 (0.44) | PDE1CPDE1APDE1BSMN1; SMN2ALDH1A1 | |
| SCHEMBL13102089 | 0.92 | P2RX7 (0.42) | PDE1CPDE1APDE1BSMN1; SMN2SIGMAR1 | |
| SCHEMBL13102083 | 0.90 | SMN1; SMN2 (0.40) | PDE1CPDE1APDE1BSMN1; SMN2SIGMAR1 | |
| SCHEMBL13102314 | 0.90 | SMN1; SMN2 (0.49) | PDE1CSMN1; SMN2SIGMAR1ALDH1A1TSHR | |
| SCHEMBL13102086 | 0.87 | SMN1; SMN2 (0.41) | SMN1; SMN2SIGMAR1ALDH1A1TSHRKDM4E | |
| SCHEMBL13102313 | 0.83 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1TSHRKDM4EMAPK1 | |
| SCHEMBL14539543 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2SIGMAR1ALDH1A1TSHRKDM4E | |
| SCHEMBL13101639 | 0.82 | SMN1; SMN2 (0.48) | PDE1CSMN1; SMN2ALDH1A1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329713-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNK17, KCNJ2, KCNJ1 | PDE1C 668/4885PDE1A 772/4885PDE1B 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.